Cangrelor Steps Up to 'Platelet,' Hits Phase III Data Home Run
Bolstering its news in January, when the firm disclosed that the intravenous antiplatelet cangrelor had proven strong in a Phase III trial as compared to oral clopidogrel, The Medicine Co.'s scientific team offered specifics over the weekend at the American College of Cardiology Scientific Session in San Francisco.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter